The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events

American Journal of Gastroenterology

Volumn 98, Issue 8, 2003, Pages 1725-1733

  Hunt, Richard H ^a   Harper, Sean ^b   Watson, Douglas J ^b   Yu, Chang ^b   Quan, Hui ^b   Lee, Michael ^b   Evans, Judith K ^b   Oxenius, Bettina ^b  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATTAPULGITE; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; DRUG SAFETY; DUODENUM ULCER; DYSPEPSIA; ENDOSCOPY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INCIDENCE; KAPLAN MEIER METHOD; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OSTEOARTHRITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; STOMACH ULCER; SURVIVAL;

EID: 0041571903     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2003.07598.x     Document Type: Article

References (28)

1. Bombardier C, Laine L, Reicin A, et al. for the VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343:1520-8.
2. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001;120:594-606.
3. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of non-steroidal antiinflammatory drugs. N Engl J Med 1999;340:1888-99 [Erratum, N Engl J Med 1999;341:548].
4. Singh G, Rosen Ramey D. NSAID induced gastrointestinal complications: The ARAMIS perspective-1997. J Rheumatol 1998;51(suppl):8-16.
5. Day R, Morrison B, Luza A, et al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Arch Intern Med 2000;160:1781-7.
6. Cannon GW, Caldwell JR, Holt P, et al. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium: Results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Arthritis Rheum 2000;43:978-87.
7. Ehrich EW, Schnitzer TJ, McIlwain H, et al. Effect of specific COX-2 inhibition in osteoarthritis of the knee: A 6 week double blind, placebo controlled pilot study of rofecoxib. J Rheumatol 1999;26:2438-47.
8. Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial. JAMA 1999;282:1921-8.
9. Laine L, Harper S, Simon T, et al. for the Rofecoxib Osteoarthritis Endoscopy Study Group A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Gastroenterology 1999;83:776-83.
10. Hawkey C, Laine L, Simon T, et al. for the Rofecoxib Osteoarthritis Endoscopy Multinational Study Group. Comparison of the effect of rofecoxib (a cyclooxygenase-2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis. Arthritis Rheum 2000;43:370-7.
11. Emery P, Zeidler H, Kvien KT, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: Randomised double-blind comparison. Lancet 1999;354:2106-11.
12. Ridolfo AS, Crabtree RE, Johnson DW, Rockhold FW. Gastrointestinal microbleeding: Comparisons between benoxaprofen and other nonsteroidal antiinflammatory agents. J Rheumatol 1980;6:36-46.
13. Hunt RH, Bowen B, Mortensen E, et al. A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects. Am J Med 2000;109:201-6.
14. Hunt RH, Harper S, Callegari P, et al. Complementary studies of the gastrointestinal safety of the cyclooxygenase-2-selective inhibitor etoricoxib. Ailment Pharmacol Ther 2003;17:201-10.
15. Silverstein FE. Improving the gastrointestinal safety of NSAIDs: The development of misoprostol-from hypothesis to clinical practice. Dig Dis Sci 1998;43:447-58.
16. Hawkey CJ, Jackson L, Harper SE, et al. The gastrointestinal safety profile of rofecoxib, a highly selective inhibitor of cyclooxygenase-2, in humans. Aliment Pharmacol Ther 2001;15:1-9.
17. Langman M, Jensen D, Watson D, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999;282:1929-33.
18. Harper S, Lee M, Curtis S, et al. A lower incidence of upper-GI perforations, ulcers and bleeds (PUBs) in patients treated with etoricoxib vs. nonselective cyclooxygenase inhibitors (NSAIDs). Arthritis Rheum 2001;44(suppl 9):S318.
19. Harper S, Bolognese J, Lee M, et al. Fewer GI-related treatment discontinuations with etoricoxib compared with nonselective cyclooxygenase inhibitors (NSAIDs). Arthritis Rheum 2001;44(suppl 9):S317.
20. Hunt RH, Bowen B, James C, et al. COX-2 specific inhibition with MK-663 120 mg q.d. over 4 weeks did not increase fecal blood loss: A controlled study with placebo and ibuprofen 800 mg. Gastroenterology 2001;120(5 Suppl 1):A-597.
21. Gottesdiener K, Schnitzer T, Fisher C, et al. MK-663, a specific COX-2 inhibitor for treatment of osteoarthritis (OA) of the knee. Arthritis Rheum 2000;42(suppl 9):S144 (abstract).
22. Malmstrom K, Shahane A, Fricke JR, Ehrich E. MK-0663, a new COX-2 inhibitor: The effect in acute pain using the dental-impaction model. Arthritis Rheum 2000;43(suppl 9):S299 (abstract).
23. Griffin MR, Piper JM, Daugherty JR, et al. Nonsteroidal antiinflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 1991;114:257-63.
24. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal antiinflammatory drugs. Ann Intern Med 1991;115:787-96.
25. Fries JF. NSAID gastropathy: The second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol 1991;18(suppl 28):6-10.
26. Taha AS, Sturrock RD, Russell RI. Mucosal erosions in long-term nonsteroidal antiinflammatory drug users: Predisposition to ulceration and relation to Helicobacter pylori. Gut 1995;36:334-6.
27. Breslow EN, Crowley J. A large sample study of the life table and product limit estimates under random censorship. Ann Stat 1974;2:437-53.
28. Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1998;338:727-34.